
Invex Therapeutics Ltd
ASX:IXC

Intrinsic Value
The intrinsic value of one
IXC
stock under the Base Case scenario is
0.04
AUD.
Compared to the current market price of 0.16 AUD,
Invex Therapeutics Ltd
is
Overvalued by 74%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Invex Therapeutics Ltd
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Invex Therapeutics Ltd
Balance Sheet Decomposition
Invex Therapeutics Ltd
Current Assets | 5.9m |
Cash & Short-Term Investments | 5.8m |
Receivables | 57.9k |
Other Current Assets | -100 |
Free Cash Flow Analysis
Invex Therapeutics Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Invex Therapeutics Ltd
Revenue
|
1.4m
AUD
|
Operating Expenses
|
-1.3m
AUD
|
Operating Income
|
114.3k
AUD
|
Other Expenses
|
0
AUD
|
Net Income
|
114.3k
AUD
|
IXC Profitability Score
Profitability Due Diligence
Invex Therapeutics Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Score
Invex Therapeutics Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
IXC Solvency Score
Solvency Due Diligence
Invex Therapeutics Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Score
Invex Therapeutics Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IXC Price Targets Summary
Invex Therapeutics Ltd
Dividends
Current shareholder yield for IXC is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IXC
stock under the Base Case scenario is
0.04
AUD.
Compared to the current market price of 0.16 AUD,
Invex Therapeutics Ltd
is
Overvalued by 74%.